Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

YouGov reiterates outlook despite 'challenging' conditions

(Sharecast News) - YouGov confirmed its full-year outlook on Friday, despite "challenging" economic conditions weighing on client budgets. Updating on interim trading, the research and analytics specialist said its performance in the six months to 31 January had been "resilient".

In particular, it noted sales momentum in the technology sector and stable demand across its data products and research divisions.

It acknowledged, however, that other sectors had been more challenging, while discretionary spend "continues to be impacted by general market softness".

It also flagged the "continued challenging macroeconomic environment".

Looking to the rest of the year, YouGov said: "The board remains cognisant of the challenging market conditions and client budget pressures as we move into the second half of the financial year."

However, it continued: "While we continue to experience long sales cycles, we remain confident in our products and sales momentum, which after a slow first quarter has significantly accelerated in the second.

"Therefore we remain confident in achieving current market expectations for the full year, underpinned by our robust sales pipeline as of January 2024."

The AIM-listed firm also gave a brief update on the acquisition of GfK's Consumer Panel Services, which completed on 9 January. YouGov said the business had been trading ahead of expectations since the deal was first announced in July, and the integration process now underway.

As at 1020 GMT, shares in YouGov were largely unchanged at 1,200p.

Share this article

Related Sharecast Articles

Eli Lilly weight-loss drug 'significantly' reduces sleep apnoea
(Sharecast News) - Eli Lily's weight-loss drug tirzepatide has been shown to "significantly" reduce sleep apnoea severity, the US drugs giant said on Wednesday.
Royal Mail-owner rebuffs takeover approach
(Sharecast News) - Shares in International Distribution Services soared on Wednesday, after it emerged that Czech billionaire Daniel Kretinsky had made a takeover approach for the Royal Mail owner.
Just Eat shares drop as Q1 orders disappoint
(Sharecast News) - Shares in Just Eat dropped sharply on Wednesday after the food delivery marketplace delivered underwhelming order numbers for the first quarter, though revenue growth picked up sharply in the UK and Ireland.
Tekcapital's Innovative Eyewear inks deal with US firm
(Sharecast News) - Intellectual property investor Tekcapital announced a fresh development from its portfolio company Innovative Eyewear on Wednesday, as the latter launched a strategic partnership with Windsor Eyes, a prominent eyewear manufacturing and distribution firm.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.